MINNEAPOLIS, MN--(MARKET WIRE)--May 5, 2009 -- Virogen, Inc. (Other OTC:VRGN.PK - News), the developer and patent holder of a revolutionary vaccine to combat the deadly Newcastle Disease that kills chickens worldwide, has received escalating inquiries for its unique Innovo Newcastle Vaccine by governments, producers, and distributors across the globe as a result of the increased demand for poultry due to the unfortunate Swine Flu outbreak.

Pork imports have been curtailed by 12 countries to date and this trend is expected to increase as countries worldwide move to protect their citizens and take further precautions against the spread of the disease. Taking a very aggressive and dramatic step, the Government of Egypt has ordered the slaughter of the entire swine population throughout the country.

As a result of these and other cautionary measures, it is anticipated, if not inevitable, that for the near term 6-12 months poultry consumption and demand will spike dramatically. This very well could create a long term change in terms of consumption worldwide as pork products could be permanently curtailed by populations everywhere in spite of dubious attempts by the World Health Organization to change the name Swine Flu to influenza A(H1N1) to avoid suggestions that eating pork products could carry a risk of infection.

As the demand for poultry increases, the possibilities for outbreaks of Newcastle Disease also increase, thus enhancing the need for Virogen's products and services. Virogen has already experienced an increase in inquiries for its flagship Innovo Newcastle Vaccine by governments, producers, and distributors across the globe. In order to fulfill the anticipated need to protect flocks around the world, the company is moving rapidly on all fronts to accommodate these recent changes in demand and market conditions. Preliminary indications are that government officials worldwide are willing to fast track the approval process for Virogen's poultry vaccines. With time lines shortened, Virogen's market opportunities are almost certain to be accelerated and significantly enhanced.

Investors and potential investors are invited to call Paul Hogan, CEO Virogen, Inc. at (415) 251-1141 to request a copy of the company's complete business plan.

Or, for Investors Relations and more information contact: Guy Vinci, VUI Consulting at 386-218-5929

Forward-Looking Statements: